Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study in Japan

AIMS/INTRODUCTION: The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial has shown the effects of canagliflozin on preventing clinically important kidney outcomes in patients with type 2 diabetes mellitus and chronic kidney disease; however,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wada, Takashi, Mori‐Anai, Kazumi, Takahashi, Akiko, Matsui, Takahiro, Inagaki, Masaya, Iida, Mitsutaka, Maruyama, Ken, Tsuda, Hidetaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720226/
https://www.ncbi.nlm.nih.gov/pubmed/35861630
http://dx.doi.org/10.1111/jdi.13888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720226/
https://www.ncbi.nlm.nih.gov/pubmed/35861630
http://dx.doi.org/10.1111/jdi.13888

Ejemplares similares